Biphasic Drug Delivery Using Bilayer Tablets for Controlled Pain Management

Abstract

Effective pain management requires a therapeutic approach capable of delivering rapid onset of action along with prolonged drug release. Conventional dosage forms are generally limited to either immediate or sustained drug delivery and fail to achieve both at the same time Immediate-release formulations provide quick relief but often require repeated administration Because of their short duration of action. In contrast, sustained-release formulations maintain drug levels over an extended period but are not suitable for conditions requiring instant relief. To overcome these limitations, biphasic drug delivery systems have been developed. These systems are designed to provide an initial loading dose followed by a maintenance dose, thereby ensuring both immediate and prolonged therapeutic effects. Among the various ways to do it bilayer tablet technology has emerged as a promising and effective method for achieving biphasic drug delivery. Bilayer tablets consist of two distinct layers compressed into a single dosage form, where one layer is formulated for immediate release and the other for sustained release. This system is particularly advantageous in pain management, as it allows rapid relief followed by prolonged therapeutic action, thereby improving patient compliance and treatment outcomes.

Keywords

Biphasic drug delivery system, Bilayer tablets, Immediate release, Sustained release, Pain management.

Introduction

Pain is a complex physiological response that significantly affects the quality of life of patients. It may arise due to injury, inflammation, or chronic disease circumstance. Effective pain management requires a dosage form that can give both immediate relief and sustained therapeutic action. Free from steroiods anti-inflammatory drugs (NSAIDs) are widely used in clinical practice as a result of their analgesic and anti-inflammatory properties. However, conventional Different forms of NSAID Medicines often fail to provide optimal therapeutic outcomes. ^[7,8]

Immediate-release formulations of NSAIDs act rapidly but require frequent dosing, which may lead to reduced patient compliance and increased risk of adverse effects. Slow-release formulations, although it can keep therapeutic drug levels, often exhibit delayed onset of action and are Not a good option for acute pain conditions.^[9,10]

In recent years, there has been increasing interest in developing advanced drug delivery systems that can overcome these limitations. Biphasic drug delivery systems represent one such approach, when two different release phases are incorporated into a single dosage form. Bilayer tablet technology is widely used for this purpose, as it allows the formulation of two layers with distinct release characteristics, thereby providing both immediate and sustained drug release. ^[11–13]

Limitations of Conventional Dosage Forms

Conventional oral dosage forms, such as tablets and capsules, are widely accepted as a result of  their ease of administration and patient convenience. However, these formulations are associated with several limitations that reduce their effectiveness in pain management. Immediate-release formulations result in rapid drug absorption followed by quick elimination, leading to a short duration of action. so, patients are required to take multiple doses throughout the day, which can reduce compliance and increase the likelihood of side effects ^[14,15].

Sustained-release formulations are designed to release the medication over an extended period. Even though they reduce dosing frequency, they often exhibit delayed onset of action, making them unsuitable for conditions requiring immediate relief.

Another major limitation is the fluctuation in plasma drug concentration. Conventional formulations often produce peaks and troughs in drug levels, which may result in Below the require dose effects or toxicity. These fluctuations can compromise treatment efficacy and patient safety. ^[16,17]

Concept of Biphasic Drug Delivery

Biphasic drug delivery systems are designed to overcome the limitations of conventional dosage forms by providing two distinct Stages of drug release. The first phase involves rapid release of the drug, ensuring immediate therapeutic action. The second phase involves sustained release, maintaining drug concentration within the therapeutic range for an extended period ^[18–20].

This dual-release mechanism is particularly beneficial in pain management, where rapid onset of action is required followed by prolonged therapeutic effect. When drug levels in plasma remains stables, biphasic release become possible systems improve treatment efficacy and reduce the risk of adverse effects.

Bilayer Tablet Technology

Bilayer tablet technology involves during compression of two distinct layers into a single tablet. Each layer is formulated independently and may contain different drugs or the same drug with different release mechanisms. This technology allows precise control over drug release and provides flexibility in formulation design ^[21–23].

The immediate-release layer is typically formulated using super disintegrants to ensure rapid drug release, even though the sustained-release layer is formulated using polymers that control drug release through diffusion, swelling, or erosion mechanisms. The combination of these two layers results in a dosage form that provides both rapid and prolonged therapeutic impact.

Formulation Considerations

The formulation of bilayer tablets requires careful selection of drugs, excipients, and polymers. Each layer must be Without help to achieve the desired release profile. Factors such as drug solubility, stability, compatibility with excipients, and flow properties must be considered ^[24–26].

Excipients such as binders, lubricants, and disintegrants play A single crucial purpose in tablet formation and performance. Correct formulation ensures uniform drug distribution and consistent release characteristics.

Polymers Used in Bilayer Tablets

Polymers are essential components of long-lasting release formulations. They control drug release by forming a matrix through which the drug diffuses. Hydrophilic polymers, such as hydroxypropyl methylcellulose, absorb water and form one gel level that control drug release. Hydrophobic polymers, such as ethyl cellulose, slow down drug release by limiting water penetration ^[27–29].

Natural polymers such as xanthan gum and guar gum are also used Because of their biocompatibility and swelling properties. The selection and concentration of polymers significantly Affect the drug release profile.

Manufacturing Techniques

Bilayer tablets are commonly manufactured using direct compression and wet granulation techniques. In bilayer compression, the first layer is compressed lightly, followed by the addition of the second layer and final compression. This sequential compression ensures proper bonding between these layers ^[30–32].

The manufacturing process must be carefully controlled to ensure uniformity, mechanical strength, and stability of the tablets.

Evaluation Parameters

The quality of bilayer tablets Act as evaluated using various pre-compression and post-compression parameters. Before compression studies include evaluation of flow properties such as

• Angle of repose,
• Bulk density
• Tapped density.

Post-compression evaluation includes

• Hardness
• Friability
• Thickness
• Weight variation
• Drug content uniformity

These parameters ensure that the tablets meet the required quality standards and are can withstand handling and transportation ^[33–35].

In-Vitro Drug Release Study

In the lab drug release studies Act as conducted to evaluate the release profile of bilayer tablets under simulated physiological conditions. The immediate-release layer is expected to release the drug rapidly, even though the sustained-release layer provides controlled drug release over an extended period ^[36–38].

The release process data Are Found to be analyzed using kinetic models to determine the How the drug is released.

Challenges in Bilayer Tablet Technology

Bilayer tablets present several challenges While formulation and manufacturing. One of the major challenges is layer separation, which occurs Owing of inadequate bonding between layers. Another challenge is maintaining adequate mechanical strength to prevent tablet damage.

Increase production of bilayer tablet manufacturing is also challenging, since it requires precise control over various process parameters ^[39–41].

Recent Advances and QbD Approach

Recent advancements in bilayer tablet technology include the use of novel polymers and advanced manufacturing way. The application of Quality by Design (QbD) principles has improved the consistency and quality of bilayer tablets by enabling systematic development and risk assessment ^[42–44].

Future Perspective

Bilayer tablet technology is expected to play a significant role in the future of drug delivery process. Advances in materials science and pharmaceutical technology will enable the development of more efficient and personalized drug transport. ^[45–47].

CONCLUSION

Biphasic drug delivery using bilayer tablets show an effective approach for controlled pain management. By combining immediate and sustained drug release in a single dosage form, bilayer tablets improve therapeutic efficacy, reduce dosing frequency, and enhance patient compliance. Continued research and development in this field are expected to further enhance the potential of bilayer tablet systems in modern Drug formulation science. ^[48–50]

REFERENCES

1. Patel A, Sharma D, Singh R. Advances in bilayer tablet technology for controlled drug delivery. Int J Pharm Sci Res. 2024;15(2):210–225.
2. Kumar V, Gupta P. Recent trends in biphasic drug delivery systems. Eur J Pharm Sci. 2024; 185:106512.
3. Mehta S, Jain N. Bilayer tablets: emerging trends in drug delivery. Drug Dev Ind Pharm. 2023;49(5):789–802.
4. Singh R, Verma K. Formulation strategies of modified release tablets. Asian J Pharm Sci. 2023;18(3):100912.
5. Gupta P, Patel M. Challenges in bilayer tablet manufacturing. J Drug Deliv Sci Technol. 2023; 78:103890.
6. Sharma D, Kumar A. Controlled drug delivery approaches for NSAIDs. Pharmaceutics. 2023;15(6):1452.
7. ICH Harmonised Guideline Q8 (R2): Pharmaceutical Development. 2022.
8. ICH Harmonised Guideline Q9: Quality Risk Management. 2022.
9. ICH Harmonised Guideline Q10: Pharmaceutical Quality System. 2022.
10. Aulton ME, Taylor K. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. Elsevier; 2022.
11. Kumar S, Singh J. Evaluation of sustained release matrix tablets. J Control Release. 2022; 345:120–135.
12. Verma A, Mishra A. NSAIDs and pain management strategies. Int J Pharm. 2022; 615:121487.
13. Patel R, Shah P. Immediate release formulations: a review. J Pharm Sci. 2022;111(4):1045–1056.
14. Singh A, Kaur R. Pharmacokinetics of Tenoxicam. Drug Res. 2022;72(2):98–105.
15. Jain N, Mehta S. Fixed dose combinations in drug delivery. Curr Drug Deliv. 2022;19(8):890–905.
16. Gupta R, Sharma S. Bilayer tablet design principles. Int J Drug Dev Res. 2021;13(2):45–58.
17. Patel M, Desai K. Drug-excipient compatibility studies. Pharm Dev Technol. 2021;26(6):675–689.
18. Kumar P, Singh V. Limitations of conventional dosage forms. Int J Pharm Sci. 2021;12(3):200–210.
19. Shah J, Patel R. Sustained release drug delivery systems. J Pharm Innova. 2021;16(4):550–565.
20. Verma S, Gupta A. Plasma drug concentration fluctuations. Eury J Drug Mehtab Pharmacokinetic. 2021;46(5):601–615.
21. Singh P, Kumar R. Biphasic drug delivery systems. J Drug Target. 2020;28(7-8):675–690.
22. Patel A, Shah M. Controlled release formulations. Drug Dev Res. 2020;81(5):620–635.
23. Sharma P, Kaur G. Immediate vs sustained drug delivery. Int J Pharm Investing. 2020;10(2):120–130.
24. Mehta R, Shah D. Pain management therapies. Clin Pharmacal. 2020; 12:45–60.
25. Desai H, Patel J. Bilayer tablet compression techniques. J Pharm Tech. 2020;36(4):210–220.
26. Gupta V, Singh R. Hydrophilic polymers in drug delivery. Plym Med. 2019;49(3):150–165.
27. Shah N, Mehta P. Ethyl cellulose applications. J Pharm Sci. 2019;108(7):2300–2310.
28. Kumar A, Verma R. Tablet evaluation parameters. Int J Pharm Res. 2019;11(2):100–110.
29. Singh D, Patel K. Dissolution testing methods. J Dissolution Technol. 2019;26(3):20–30.
30. Jain S, Gupta M. Drug release kinetics models. J Control Release. 2019; 300:50–65.
31. Sharma R, Singh P. Challenges in scale-up manufacturing. Pharm Eng. 2018;38(2):30–40.
32. Patel D, Shah H. Mechanical strength of tablets. Int J Pharm Sci. 2018;10(5):250–260.
33. Verma K, Singh A. Layer separation in bilayer tablets. Drug Dev Ind Pharm. 2018;44(6):900–910.
34. Gupta S, Mehta A. Advances in polymer science. Prog Plym Sci. 2018; 85:1–25.
35. Singh V, Kumar N. Bilayer tablet applications. J Pharm Innova. 2018;13(3):200–215.
36. Patel S, Shah R. Drug delivery innovations. Adv Drug Deliv Rev. 2017; 120:1–15.
37. Sharma A, Gupta N. NSAID delivery systems. Drug Disco Today. 2017;22(6):900–910.
38. Kumar D, Singh S. Controlled drug release systems. J Pharm Sci. 2017;106(9):2450–2460.
39. Verma R, Jain P. Tablet formulation techniques. Int J Pharm. 2017;530(1-2):150–160.
40. Shah P, Patel M. Role of excipients. Pharm Dev Technol. 2017;22(4):450–460.
41. Gupta A, Singh B. Drug stability studies. J Pharm Biomed Anal. 2016; 130:400–410.
42. Patel N, Shah K. Dissolution profile analysis. Int J Pharm Sci Rev Res. 2016;40(2):150–160.
43. Kumar R, Sharma V. Modified drug delivery systems. Drug Dev Ind Pharm. 2016;42(5):700–710.
44. Singh J, Verma P. Matrix tablets review. J Control Release. 2016; 240:1–10.
45. Mehta P, Shah J. Bilayer tablets overview. Int J Pharm Sci. 2016;8(3):10–20.
46. Lachman L, Lieberman H. Theory and Practice of Industrial Pharmacy. CBS; 2015.
47. Remington JP. Remington: The Science and Practice of Pharmacy. 22nd ed. 2015.
48. Banker GS, Rhodes CT. Modern Pharmaceutics. CRC Press; 2015.
49. Robinson JR, Lee VHL. Controlled Drug Delivery. 2014.
50. Chien YW. Novel Drug Delivery Systems. 2014